Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
University of California, Davis
Essen Biotech
Institut Bergonié
OSE Immunotherapeutics
M.D. Anderson Cancer Center
University of Salamanca
Incyte Corporation
Immunitas Therapeutics
Washington University School of Medicine
Incyte Corporation
Washington University School of Medicine
Trishula Therapeutics, Inc.
Novartis
Novartis
Intensity Therapeutics, Inc.
Zealand University Hospital
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Janssen Research & Development, LLC
RAPT Therapeutics, Inc.
University of Toronto
Cedars-Sinai Medical Center
Pfizer
TopAlliance Biosciences
Rutgers, The State University of New Jersey
Eastern Cooperative Oncology Group
Seagen Inc.
Fate Therapeutics
ImmVira Pharma Co. Ltd
Blue Note Therapeutics
Novartis
Università Politecnica delle Marche
Eli Lilly and Company
Incyte Corporation
University Health Network, Toronto
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Institut Bergonié
Amgen
Mid and South Essex NHS Foundation Trust
Curis, Inc.
MultiVir, Inc.
Celgene
Case Comprehensive Cancer Center
Tocagen Inc.
University of Wisconsin, Madison
Shenzhen BinDeBio Ltd.
Shanghai Junshi Bioscience Co., Ltd.
Mayo Clinic